Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress

The decrease of NAD(P)H:quinone oxidoreductase 1 activity and increase of ROS production by NADPH oxidases are early biomarkers in doxorubicin cardiotoxicity

“…1.A), in accordance with those described in the bibliography for doxorubicin-induced cardiomyopathy (Andreadou et al 2007;Takemura & Fujiwara 2007;Sterba et al 2013). At day 5 after drug administration, some cardiomyocytes with vacuolization and an abnormal morphology possibly due to myofibrillar disarrangement, could be observed in the stained heart sections.…”

“…This dose was selected after preliminary studies carried out in our laboratory with doses ranging from 10 to 40 mg of doxorubicin/kg body weight, aiming to set up a suitable protocol to detect the first, moderate but specific, signs of doxorubicin cardiotoxicity without a severe impairment of the animals. Equal or very similar doses are also used by other authors to investigate the effects of the drug in the heart and possible cardio protectors (Sadzuka et al 1997;Mihm et al 2002;Xiong et al 2006;Andreadou et al 2007;Ichihara et al 2007;Diotte et al 2009;Huelsenbeck et al 2011;Mokni et al 2012). …”

“…S.1.A of Supplementary Data), in good agreement with the results obtained for GSH levels which were also unaffected by the treatment, as shown in the Table 1. A study by other authors suggested an increase in protein carbonylation induced by doxorubicin in vivo (Andreadou et al 2007). However, in our experimental conditions we did not detect an increase in the levels of protein carbonyls in heart homogenates until day 7 post-injection of doxorubicin using both the spectrophotometric and the Western blotting method with DNPH derivatization ( …”

Impact of Consumption of Olive and Argane Oils on Anthropometric Profile of Postmenopausal Women in Morocco

“…Oleuropein have several pharmacological properties, including anti-oxidant [33,34] and anti-atherogenic [12]; and for these reasons, it is commercially available as a dietary supplement in the Mediterranean countries. In addition, it has been shown that oleuropein has cardio-protective effect against acute cardiovascular toxicity of adriamycin [35] and also an anti-ischemic…”

Hematologic Toxicosis; Induced by Doxorubicin Protective Effects of Combination of Olea Europeae and Ginkgo Biloba

“…Phenolic constituents including oleuropein, hydroxytyrosol and tyrosol were responsible for most of the olive pharmacologic activities. 6 The extract in a time and dose dependent manner have decreased proliferation and possess cytotoxic effects, 7 also inhibits production of ROS, decrease in the production of Thromboxane A2, anti-inflammatory and inhibition of platelet aggregation, 8 reduces infarct size, 9 produces antioxidant effect. 6 The extract of Olea europeae put forth a defensive process by reducing the DOX cardiotoxicity which was articulated by the changes in peripheral and intracellular markers.…”